Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 351–400 of 523 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT01446900	R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia…	Phase 2	terminated	Oct 5, 2011	European Institute of Oncology	low rate in patient accrual	Enrollment / accrual
NCT02815059	Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and…	Phase 1	withdrawn	Jun 28, 2016	University of Utah	Termination of Investigator Initiated Studies using Ibrutinib	Investigator
NCT02200848	Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic…	Phase 1	terminated	Jul 25, 2014	Georgetown University	Recruitment difficulties and toxicity	Safety / toxicity
NCT01564277	Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies	Phase 2	terminated	Mar 27, 2012	Roswell Park Cancer Institute	low accrual	Enrollment / accrual
NCT01312818	Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic…	Phase 2	terminated	Mar 11, 2011	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT01207076	AHN-12 Biodistribution in Advanced Leukemia	Phase 1	terminated	Sep 22, 2010	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT02765997	StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies	Phase 2	withdrawn	May 9, 2016	Masonic Cancer Center, University of Minnesota	IRB Disapproval	Other (stated, no rule matched)
NCT01163201	T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in…	Phase 1 / Phase 2	withdrawn	Jul 15, 2010	Masonic Cancer Center, University of Minnesota	Replaced by a new study	Other (stated, no rule matched)
NCT01677949	Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute…	Phase 2	withdrawn	Sep 3, 2012	Masonic Cancer Center, University of Minnesota	Slow accrual	Enrollment / accrual
NCT02662296	Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic…	Phase 2	withdrawn	Jan 25, 2016	Fred Hutchinson Cancer Center	Low enrollment	Enrollment / accrual
NCT02677948	Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic…	Phase 1 / Phase 2	withdrawn	Feb 9, 2016	University of Michigan Rogel Cancer Center	FDA has placed all trials involving Pacritinib on Full Clinical Hold	Other (stated, no rule matched)
NCT01383447	Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory…	Phase 1 / Phase 2	terminated	Jun 28, 2011	National Cancer Institute (NCI)	This study was halted prematurely by the NCI for low accrual.	Enrollment / accrual
NCT01419795	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed…	Phase 2	terminated	Aug 18, 2011	Fred Hutchinson Cancer Center	Low accrual	Enrollment / accrual
NCT03141398	Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in…(CGMs)	—	withdrawn	May 5, 2017	Hamad Medical Corporation	Due to issues with study design	Other (stated, no rule matched)
NCT00587457	A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic…	Phase 1	terminated	Jan 7, 2008	MedImmune LLC	The study is terminated early due to unavailability of investigational product.	Other (stated, no rule matched)
NCT00496132	A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or…	Phase 1 / Phase 2	terminated	Jul 4, 2007	Genentech, Inc.	not stated	Not stated
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A…	N/A	terminated	Feb 26, 2010	Fred Hutchinson Cancer Center	Funding withdrawal	Funding
NCT02647190	Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed…	Phase 1	withdrawn	Jan 6, 2016	Memorial Sloan Kettering Cancer Center	not stated	Not stated
NCT02259348	Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following…	Phase 2	terminated	Oct 8, 2014	St. Jude Children's Research Hospital	Investigator's decision.	Investigator
NCT01625455	Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary…	Phase 4	terminated	Jun 21, 2012	Vanderbilt University Medical Center	Difficulty recruiting.	Enrollment / accrual
NCT01610999	Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell…	Phase 1	terminated	Jun 4, 2012	Tufts Medical Center	Unavailability of study article	Other (stated, no rule matched)
NCT02371577	Evaluation of the Immune Restoration Potential Of Lenalidomide(Revlimid)	Phase 2	withdrawn	Feb 25, 2015	University of California, San Diego	withdrawn	Other (stated, no rule matched)
NCT01173679	Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL	Phase 2	terminated	Aug 2, 2010	Massachusetts General Hospital	Slow accrual	Enrollment / accrual
NCT00596336	Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application…(CLLIFVAC)	Phase 2	terminated	Jan 17, 2008	The Royal Bournemouth Hospital	Recruitment issues	Enrollment / accrual
NCT02973191	A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With…(ORBIT)	Phase 1 / Phase 2	withdrawn	Nov 25, 2016	Celgene	Development of JCAR015 has been discontinued. No subjects were enrolled/treated under protocol…	Enrollment / accrual
NCT02200380	A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell…	Phase 2	terminated	Jul 25, 2014	Celldex Therapeutics	not stated	Not stated
NCT02227108	Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia…	Phase 2	terminated	Aug 27, 2014	MedImmune LLC	The study was terminated prior to a planned interim analysis based on lack of required efficacy in…	Efficacy / futility
NCT00360776	Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte…	Phase 2	terminated	Aug 7, 2006	National Cancer Institute (NCI)	not stated	Not stated
NCT02285244	Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic…	Phase 2	withdrawn	Nov 6, 2014	James Blachly	Decision made by the Principal Investigator	Investigator
NCT02257684	A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as…	Phase 2	terminated	Oct 6, 2014	Jazz Pharmaceuticals	Sponsor decision	Sponsor / business decision
NCT01944943	Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or…(VISMOLY)	Phase 2	terminated	Sep 18, 2013	The Lymphoma Academic Research Organisation	lack of efficacy	Efficacy / futility
NCT01749111	Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin…(CICLODECH)	Phase 3	terminated	Dec 13, 2012	Hospital Israelita Albert Einstein	Lack of accrual	Enrollment / accrual
NCT01621477	T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell…	Phase 2	terminated	Jun 18, 2012	St. Jude Children's Research Hospital	Study was terminated in August 2016 due to replacement by a new study.	Other (stated, no rule matched)
NCT02167360	Study of Efficacy and Safety of CTL019 in Adult ALL Patients	Phase 2	withdrawn	Jun 19, 2014	Abramson Cancer Center at Penn Medicine	Did not enroll	Enrollment / accrual
NCT02129062	Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic…	Phase 2	terminated	May 2, 2014	National Cancer Institute (NCI)	Slow accrual.	Enrollment / accrual
NCT02086591	A Phase II Study of Doxycycline in Relapsed NHL	Phase 2	terminated	Mar 13, 2014	University of Rochester	Lack of accrual	Enrollment / accrual
NCT01600053	Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia	Phase 2	terminated	May 16, 2012	Thomas Kipps	interim analysis showed that the trial will not meet the interim endpoint.	Efficacy / futility
NCT02861040	Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or…	Phase 1	withdrawn	Aug 10, 2016	Northwestern University	not stated	Not stated
NCT01401322	Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic…	Phase 2	terminated	Jul 25, 2011	Stanford University	low accrual	Enrollment / accrual
NCT00098371	Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic…	Phase 2	terminated	Dec 8, 2004	National Cancer Institute (NCI)	CTEP Initiated Action.	Other (stated, no rule matched)
NCT00278265	Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic…	Phase 2	terminated	Jan 18, 2006	German CLL Study Group	slow recruitment	Enrollment / accrual
NCT00281931	Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic…	Phase 2	terminated	Jan 25, 2006	German CLL Study Group	not stated	Not stated
NCT00416910	Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic…	Phase 3	terminated	Dec 28, 2006	German CLL Study Group	low recruitment	Enrollment / accrual
NCT00771056	Hydroxychloroquine in Untreated B-CLL Patients	Phase 2	terminated	Oct 10, 2008	Northwell Health	study suspended while data is reviewed for safety and efficacy.	Safety / toxicity
NCT02281279	Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory…	Phase 1 / Phase 2	withdrawn	Nov 3, 2014	Mayo Clinic	not stated	Not stated
NCT02640833	A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic…	Phase 1	withdrawn	Dec 29, 2015	AbbVie	Study Stopped	Other (stated, no rule matched)
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With…	Phase 2	withdrawn	Jul 27, 2012	University of Medicine and Dentistry of New Jersey	Funding unavailable	Funding
NCT02046928	Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia…	Phase 2	terminated	Jan 28, 2014	Ångstrom Pharmaceuticals	Slow enrollment	Enrollment / accrual
NCT01649791	Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell…	N/A	terminated	Jul 25, 2012	Roswell Park Cancer Institute	not stated	Not stated
NCT02273856	Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic…(NADIR)	—	terminated	Oct 24, 2014	Astellas Pharma International B.V.	The study was terminated due to insufficient subject enrollment and very slow enrollment.	Enrollment / accrual

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 23 days agoSource updated Jan 31, 2018source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules